Tonix Pharma Presents Data From Analysis Of Phase 3 RELIEF And RESILIENT Studies Of TONMYA For Treatment Of Fibromyalgia In Adults, At IASP 2026 World Congress

TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies

Tonix commercially launched TONMYA® in November 2025, the first fibromyalgia drug for adults in the U.S. in over 15 years approved by the U.S. Food and Drug Administration (FDA)

BERKELEY HEIGHTS, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated, commercial-stage biopharmaceutical company, presented data from an analysis of the Phase 3 RELIEF and RESILIENT studies of TONMYA® (cyclobenzaprine HCl sublingual tablets) for the treatment of fibromyalgia in adults demonstrating outcomes as measured by the Fibromyalgia Impact Questionnaire-Revised (FIQR) at the International Association for the Study of Pain (IASP) 2026 World Congress on Pain, held October 26-30, 2026, in Bangkok, Thailand.